Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-3373 vs Adalimumab in Moderate to Severe RA
NCT03823391Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2019
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of ABBV-3373 in rheumatoid arthritis (RA), sponsored by AbbVie Inc.. Started Mar 2019; status: completed.
02
Drugs
ABBV-3373
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03823391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03823391.